BioSpace News Archive

According to the report, the global bioremediation technology & services market was valued at ~US$ 9 Bn in 2019.

Blood culture tests are conducted when a healthcare provider suspects that a patient might suffer from blood infection.

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that it has achieved full enrollment in its Phase 3 DeFi trial evaluating nirogacestat, an investigational gamma secretase inhibitor, in adult patients with progressing desmoid tumors.

Generation Bio Co . (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced that Matthew Norkunas, M.D., MBA, has been appointed chief financial officer. “We are delighted to add Matt’s broad strategic perspective and deep operational experience to our team as we prepare the platform for our journey to the clinic,” said Geoff McDonough, M.D., president and chief executive of

Seer, Inc. announced the publication in Nature Communications of a study demonstrating the power of its proprietary, engineered nanoparticle technology platform to discover novel proteins and biomarkers through an unprecedented combination of unbiased, deep, rapid, large-scale proteomics.

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced next steps in the clinical development of the Company’s potential treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene following receipt of written feedback from the FDA

Mach7 Technologies, Inc., a leading provider of data management and enterprise imaging solutions for healthcare providers, announced today that it has completed its acquisition of Client Outlook Inc., an Ontario-based company focused on the development of eUnity, a cutting edge, zero-footprint viewing and integration platform distinguished as healthcare’s first Smartviewer

Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that it has closed a one-year extension of the maturity date of its debenture. Mr. Donald McCaffrey, President and CEO stated, “We are very pleased that the debenture has been extended for one year, providing us with greater flexibility to create value for our shareholders through both our FDA approved BETonMACE2 final planning and our ongoing partnering discussions.

BD Onclarity™ HPV Assay is the only FDA-approved HPV assay to individually identify and report genotypes beyond 16, 18 and 45

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that SPRAVATO®, following a Notice of Compliance from Health Canada, is now available for Canadian patients.